Abstract:Rett syndrome is a neurodevelopmental disorder typically caused by mutations in methyl-CpG-binding protein 2 (MECP2) in which 26% of deaths are sudden and of unknown cause. To explore the hypothesis that these deaths may be due to cardiac dysfunction, we characterized the electrocardiograms in 379 people with Rett syndrome and found that 18.5% show prolongation of the corrected QT interval (QTc), an indication of a repolarization abnormality that can predispose to the development of an unstable fatal cardiac rhythm. Male mice lacking MeCP2 function, Mecp2(Null/Y), also have prolonged QTc and show increased susceptibility to induced ventricular tachycardia. Female heterozygous null mice, Mecp2(Null/+), show an age-dependent prolongation of QTc associated with ventricular tachycardia and cardiac-related death. Genetic deletion of MeCP2 function in only the nervous system was sufficient to cause long QTc and ventricular tachycardia, implicating neuronally mediated changes to cardiac electrical conduction as a potential cause of ventricular tachycardia in Rett syndrome. The standard therapy for prolonged QTc in Rett syndrome, β-adrenergic receptor blockers, did not prevent ventricular tachycardia in Mecp2(Null/Y) mice. To determine whether an alternative therapy would be more appropriate, we characterized cardiomyocytes from Mecp2(Null/Y) mice and found increased persistent sodium current, which was normalized when cells were treated with the sodium channel-blocking anti-seizure drug phenytoin. Treatment with phenytoin reduced both QTc and sustained ventricular tachycardia in Mecp2(Null/Y) mice. These results demonstrate that cardiac abnormalities in Rett syndrome are secondary to abnormal nervous system control, which leads to increased persistent sodium current. Our findings suggest that treatment in people with Rett syndrome would be more effective if it targeted the increased persistent sodium current to prevent lethal cardiac arrhythmias.

Non-canonical C-terminal variant of MeCP2 R344W exhibits enhanced degradation rate

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

MECP2 Mutation Spectrum and Its Clinical Characteristics in a Chinese Cohort

A novel pathogenic mutation of MeCP2 impairs chromatin association independent of protein levels

Rett Syndrome Mutation Mecp2 T158a Disrupts Dna Binding, Protein Stability and Erp Responses

Graded and pan-neural disease phenotypes of Rett Syndrome linked with dosage of functional MeCP2

Testing the PEST hypothesis using relevant Rett mutations in MeCP2 E1 and E2 isoforms

MECP2 and CDKL5 Gene Mutation Analysis in Chinese Patients with Rett Syndrome

Regulation Mechanism and Research Progress of MeCP2 in Rett Syndrome

MECP2 Gene Mutation Analysis in Chinese Patients with Rett Syndrome

Mutations in MECP2 Exon 1 in Classical Rett Patients Disrupt MECP2_e1 Transcription, but Not Transcription of MECP2_e2

MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex

MeCP2 Deficiency in Neuroglia: New Progress in the Pathogenesis of Rett Syndrome.

Rett Syndrome Linked to Defects in Forming the MeCP2/Rbfox/LASR Complex in Mouse Models

Molecular Genetic Study of MECP2 Gene for a Patient with Typical Rett Syndrome

Pathogenesis of lethal cardiac arrhythmias in Mecp2 mutant mice: implication for therapy in Rett syndrome

Loss of O-GlcNAcylation on MeCP2 at Threonine 203 Leads to Neurodevelopmental Disorders

Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes

Rett Syndrome-Causing Mutations Compromise MeCP2-mediated Liquid–liquid Phase Separation of Chromatin

Electrophysiological Phenotypes of MeCP2 A140V Mutant Mouse Model